Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 9/20 | 0.37 |
| ▸ | HTR6 | P50406 | 6/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.36 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 4/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TEK | Q02763 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798579 | 1.00 | ACVR1 (0.37) | ACVR1HTR6SMN1; SMN2BMPR1BBMPR1A | |
| SCHEMBL8176428 | 1.00 | ACVR1 (0.37) | ACVR1HTR6SMN1; SMN2BMPR1BBMPR1A | |
| SCHEMBL8181787 | 0.96 | HTR6 (0.36) | ACVR1HTR6SMN1; SMN2BMPR1BBMPR1A | |
| SCHEMBL1798465 | 0.96 | HTR6 (0.36) | ACVR1HTR6SMN1; SMN2BMPR1BBMPR1A | |
| SCHEMBL1798466 | 0.96 | HTR6 (0.36) | ACVR1HTR6SMN1; SMN2BMPR1BBMPR1A | |
| SCHEMBL8181794 | 0.94 | MAPK8 (0.39) | ACVR1HTR6SMN1; SMN2BMPR1BBMPR1A | |
| SCHEMBL1799201 | 0.94 | MAPK8 (0.39) | ACVR1HTR6SMN1; SMN2BMPR1BBMPR1A | |
| SCHEMBL1799200 | 0.94 | MAPK8 (0.39) | ACVR1HTR6SMN1; SMN2BMPR1BBMPR1A | |
| SCHEMBL1798453 | 0.92 | MAPK8 (0.42) | ACVR1HTR6BMPR1BBMPR1AACVR1B | |
| SCHEMBL1798455 | 0.92 | MAPK8 (0.42) | ACVR1HTR6BMPR1BBMPR1AACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | ACVR1 4459/4885HTR6 2021/4885SMN1; SMN2 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.